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Abstract: Bovine lactoferrin (LF) has been shown to prevent adhesion to and invasion of mammalian
cell lines by pathogenic bacteria, with evidence for direct bacterial binding by the milk glycoprotein.
However, the glycosylation pattern of LF changes over the lactation cycle. In this study, we
aim to investigate the effect that this variation has on the milk glycoprotein’s ability to interact
with pathogens. Surface plasmon resonance technology was employed to compare the binding
of LF from colostrum (early lactation) and mature milk (late lactation) to a panel of pathogenic
bacteria (Staphylococcus aureus, Escherichia coli, Cronobacter sakazakii, Streptococcus pneumoniae,
Pseudomonas aeruginosa, Listeria monocytogenes and Salmonella typhimurium). Novel interactions with
LF were identified for C. sakazakii, S. pneumoniae and P. aeruginosa with the highest binding ability
observed for mature milk LF in all cases, with the exception of S. typhimurium. The difference
in bacterial binding observed may be as a result of the varying glycosylation profiles. This work
demonstrates the potential of LF as a functional food ingredient to prevent bacterial infection.
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1. Introduction
Bovine milk lactoferrin (LF) is a single chain, iron-binding, glycosylated protein [1] present
in the whey protein fraction of milk [2] (http://www.uniprot.org/uniprot/B9VPZ5). There are
two lactoferrin variants present in bovine milk: LF-a and LF-b. Five glycosylation potential
sites (Asn233, Asn281, Asn368, Asn476 and Asn545) were identified through a combination of
digestion and HPLC on LF, of which four are always utilised but Asn281 is glycosylated only on
LF-a [3–5]. Lactoferrin may have high-mannose type, complex type or hybrid type N-linked glycans
attached. The associated glycan chains are composed of N-acetyl-glucosamine (GlcNAc), galactose
(Gal), N-acetyl-galactosamine (GalNAc), fucose (Fuc), mannose (Man), N-acetyl-neuraminic acid
(Neu5Ac) and N-glycolyl-neuraminic acid (Neu5Gc) (as previously reviewed [6]) and variation in
the glycosylation pattern of LF has been described over the lactation cycle [7]. A greater degree of
heterogeneity in glycan structure has been reported for LF from early lactation, with an abundance
of high-mannose type glycans present on th glycoprotein in mature milk [7]. The glycan chains in
mature milk LF are 65% oligomannose type, consisting of multiple isomers of high-mannose type
glycans, containing five to nine mannose residues, 38% of the total mannose structures accounted for
by Man8 [8]. Neu5Gc was shown to be present on bovine LF only in the initial days postpartum and
the total sialic acid content decreased as lactation progressed [7].
LF has a wide variety of associated biological activities including antimicrobial [9],
immunomodulatory [10], prebiotic [11,12], stimulation of bone formation [13] and anticancer [14,15].
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These bioactivities have previously been reviewed by several authors [16,17] and the glycan component
of LF has an important role to play in many of these properties [6]. The presence of the glycan
chains influences the tertiary structure of the protein, and enhances its ion binding ability [18–20]
and its resistance to enzyme digestion [21]. The attached glycans are also believed to have a role
in LF’s antibacterial [22–24] and antiviral [25,26] activities. However, to date, information on how
glycosylation variation over lactation influences bioactivity is limited.
Biomolecular interaction analysis (Biacore) involves the use of surface plasmon resonance (SPR) to
measure the binding of candidate compounds or cells to specific ligands. SPR measures the changes in
the refractive index near a planar chip surface induced by binding of soluble molecules to immobilized
counterpart molecules on the sensor chip [27]. It has been widely used for the quantification and
kinetic analysis of receptor-ligand interactions [28–33]. Recently, this methodology has been identified
as a reliable, high throughput method for profiling the interaction of whole bacterial cells with an
immobilised glycans [28]. The authors validated the Biacore assay by investigating the interaction
between Campylobacter jejuni and the milk oligosaccharide, 2’-fucosyllactose, to which it is known
to bind [34,35]. The assay monitors interactions dynamically over time in a continuous flow system
and may mimic natural conditions in a more realistic manner when compared with static adhesion
assays [28]. A number of similar studies to monitor whole bacterial cell interactions with immobilised
compounds of interest have also been documented [36–39]. Of particular interest is a study using
SPR to distinguish between five closely related Escherichia coli strains, including the enterohemorragic
E. coli O157:H7 based on direct differential carbohydrate recognitions [40].
The current study aims to exploit SPR to investigate the importance of the glycan chains in
the interaction between LF and bacteria. Commercially available LF from colostrum and mature
bovine milk was biotinylated and immobilised on the streptavidin coated surface of a Streptavidin
SA chip. A number of pathogenic bacterial strains were selected and screened for interactions with
both glycovariants.
2. Materials and Methods
2.1. Materials
LF from colostrum and mature milk was purchased from Sigma-Aldrich Co. (Dublin, Ireland).
Mueller-Hinton broth and Brain Heart Infusion broth were purchased from Oxoid (Basingstoke,
Hampshire, UK). The Biacore X instrument, SA chip, biotin CAPture kit, HBS-EP buffer (10 mmol·L−1
Hepes, 150 mmol·L−1 NaCl, 3.8 mmol·L−1 ethylenediaminetetraacetic acid (EDTA), 0.05% (v/v)
Tween 20), and amine coupling kit were purchased from GE Healthcare (Buckinghamshire, UK).
The EZ-Link biotin-PEG4-hydrazide kit, sodium acetate buffer (pH 5.5), and Zeba desalt spin column
were purchased from Pierce (Rockford, IL, USA). Sodium meta-periodate was purchased from
Sigma-Aldrich Co. (Dublin, Ireland).
2.2. Bacterial Strains and Culture Conditions
Bacterial strains used in this study and their respective growth media are listed in Table 1.
Bacterial culture stocks were maintained in their respective growth media containing 50% glycerol
at −80 ◦C in the culture collection at Teagasc Food Research Centre, Moorepark, Fermoy, P61C996, Co.
Cork, Ireland and propagated twice prior to use. All bacterial strains were grown aerobically for 12–24 h
at 37 ◦C. Bacterial cells were washed three times in HBS–EP buffer and re-suspended to a concentration
of 1 × 108 colony-forming units (CFU) mL−1 for screening studies unless otherwise stated.
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Table 1. List of bacterial strains tested.
Strain Media
Staphylococcus aureus DPC 5971 Muller-Hinton
Escherichia coli O157:H7 P1432 Muller-Hinton
Escherichia coli O157:H7 NCTC 12900 Muller-Hinton
Cronobacter sakazakii NCTC 8155 Brain Heart Infusion
Cronobacter sakazakii DPC 6531 Brain Heart Infusion
Streptococcus pneumoniae ATCC BAA-255 Todd Hewitt + 0.5% yeast extract
Pseudomonas aeruginosa ATCC 33354 Tryptic soy broth
Salmonella enterica subsp. enterica serovar
Typhimurium ATCC BAA-185 Brain Heart Infusion
Listeria monocytogenes DPC 3437 Brain Heart Infusion
Listeria monocytogenes NCTC 11994 Brain Heart Infusion
2.3. Biotinylation of Lactoferrin
LF samples were biotinylated using EZLink biotin-PEG4-hydrazide as per the manufacturer’s
instructions. Briefly, 2 mg of LF was dissolved in 1 mL of 0.1 mol·L−1 sodium acetate buffer (pH 5.5).
An amount of 1 mL of cold sodium meta-periodate solution (20 mmol·L−1 periodate) was added
and the solution was mixed well. The mixture was protected from light and incubated for 30 min at
room temperature. Excess periodate was removed using a Zeba desalt spin column equilibrated with
0.1 mol·L−1 sodium acetate buffer (pH 5.5). One part of 50 mmol L−1 biotin-hydrazide solution was
added to nine parts of the treated sample and incubated for 3–4 h at room temperature. Unbound
biotin remaining in the sample was removed by passing the solution sequentially through two Zeba
desalt spin columns. The sample was then stored at 4 ◦C until use.
2.4. Biacore Assay
The entire analysis was carried out on a Biacore X instrument at a constant temperature (25 ◦C)
and flow rate (10 µL·min−1), unless otherwise stated, using HBS–EP as the run buffer and a SA chip.
The streptavidin-coated SA chip surface was primed with a short injection of 1 mol·L−1 NaCl and
50 mmol·L−1 NaOH (filtered and degassed). Whole bacterial cells were harvested and resuspended in
HBS–EP running buffer as described in Section 2.2. In order to confirm the absence of non-specific
binding of the selected bacterial strains to the SA chip surface, cell suspensions (1 × 108 CFU mL−1)
were injected over the chip surface at 10·µL·min−1, and the binding signal was measured. Signal
change was reported in response units (RU). The chip surface was washed with HBS–EP running
buffer between bacterial injections to ensure full removal of microbial cells.
Thereafter, biotin-labelled LF (from either colostrum or mature milk) was diluted in HBS–EP buffer
(50 µg·mL−1), and 100 µL of this solution was injected over the surface at a flow rate of 10 µL·min−1.
The chip surface was then washed with HBS–EP buffer to ensure the removal of any non-immobilized
molecules. The RU increase following each LF injection was monitored to ensure comparable levels
of analyte were immobilised. Subsequently, bacterial injections were repeated to evaluate bacterial
binding to immobilised colostrum and mature milk LF.
2.5. Statistical Analysis
All experiments were performed in triplicate and results are presented as mean values± standard
deviations of three replicate experiments. Nonspecific binding of the analyte to the test surface was
eliminated from all experiments through the use of a reference surface.
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3. Results
In the current study, SPR was used to investigate the effect of changes in LF glycosylation over
lactation on its ability to bind to pathogenic bacteria. A panel of pathogenic bacteria was initially
exposed to the surface of the SA chip, minus the immobilised analyte, to ensure the absence of
non-specific binding to the chip surface, which could result in false results during the test runs.
Bacterial solutions were washed and resuspended in buffer prior to exposure to the chip surface to
ensure no salts were present in the samples. The chip was also washed between exposures to different
bacterial strains and also on a daily basis. The system was also optimized in terms of the flow rate
to ensure that cell deposition did not occur. For all bacteria screened, non-specific binding was not
observed (data not shown). Concentrations of bacteria at approximately 1 × 108 CFU·mL−1 were used
in the assays as previous studies have shown that concentrations in this range are generally required
to generate a measurable signal [28].
Based on previous studies [23,41,42] and the results generated in the initial phase of this work,
S. aureus DPC 5971 and E. coli P1432 were identified as positive and negative controls for binding to LF
respectively. Exposure of bacterial suspensions with increasing cell number resulted in an increase
in the RU value with S. aureus DPC 5971, confirming that the injected bacterial cells were interacting
with the immobilised LF (Figure 1). It should be noted that at the end of the injection period of 600 s,
the RU values were maintained before a gradual decline in RU was observed, indicating the specific
nature of the interactions (data not shown).
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Figure 1. Increasing concentrations of Staphylococcus aureus DPC 5971 (red) and Escherichia coli O157:H7
P1432 (blue) injected over the surface of a streptavidin (SA) chip with mature LF immobilised to
evaluate effect of increasing bacterial numbers on the response units (RU) response.
No increase in RU value was observed for E. coli P1432 following exposure of increasing
concentrations of ct ri l t i obilised LF (Figure 1), confirming the lack of bi ding of
this strain to the analyte. The e strains were exposed to the surface of the SA chip with i mob lised LF
a the begi ning of each experimental se to ensure con istent performance of the chip. The response
of E. coli P1432 (colostrum: 16.8 ± 4.3 RU; mature milk: 17 ± 7.1) was considered baseline mini um
RU value and used s a reference for screening the other pathogens for positive interactions.
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RU changes following exposure of the bacterial strains to the immobilised colostrum and mature
milk LF are shown in Figure 2. Of the positive interactions profiled, the strongest signals were observed
for C. sakazakii NCTC 8155, S. pneumoniae ATCC BAA-255 and P. aeruginosa ATCC 33354. Neither
L. monocytogenes strain tested displayed binding to either LF glycovariant. For the majority of strains
which displayed positive binding, a stronger interaction was observed for mature milk LF versus
colostrum LF. S. typhimurium ATCC BAA-185 was the sole exception to this, interacting only with the
glycovariant of the protein isolated from colostrum.
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4. Discussion
The greater interaction with mature LF may be linked to the abundance of high-mannose
type glycans on this glycovariant. Teraguchi, Shin, Fukuwatari and Shimamura [23] described the
relationship between LF and members of the Escherichia family and the dependence of the observed
interaction on the presence of high-mannose type glycans on the milk protein. Members of this family
which express type 1 fimbriae can recognise and bind to oligomannose glycan chains on eukaryotic cell
surfaces [43], which can facilitate bacterial adhesion to and i vasion of the cells. Teraguchi et al. [23]
demonstrated that the high mannose-type glycans on bovine LF acted as receptors for the mannose
specific type 1 fimbriae, therefore preventing bacterial i teraction with the eukaryotic cell by acting as
a dec y receptor. When human LF was tested, this activity was ot observed, potentially as a result
of the presence of only complex type glycans on the protein variant. The same group went
on to demonstrate th t bovine LF caused the agglutinati n of type 1 fimbriated E. coli cells as a result
of the specific interaction between the a nose residues o the glycoprotein and the type 1 fimbriae
of the bacteria. The results presented here suggest th t b vin LF may also have similar interactions
with oth r p thogenic bacteria as a result of its direct bacterial int raction via its oligomannose type
glyc ns. The glycoprotein may have a role as a more on-specific defence mechanism, inhibiting
bacterial adhesion to ma malian cells.
The low r binding observed for LF isolated from early lactation ay also b linked to the presence
of mor diverse a timicrobial elements in c lostrum such as immunoglobulins and oligosaccharid s.
Therefore, there may be less of a biological r quirement for LF to ontribute to the inhibitio of
pathogenic infection. Also, the presence of sialic acid on colostru LF glycans suggests that this
glycovariant may have an alter ative method of anti-bacteri l activity in early lactation. Sialylation
has previously bee linked to LF’s ntimicrobial activity as a result of its alcium chelation activity,
competi g for loosely bound calcium ions involved in the stabilization of lipopolysaccharides in the
outer membrane of bact rial cells [18,44].
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S. aureus DPC 5971 is a bovine mastitis isolate [45] and was selected as the positive control for
this study as receptors for LF have previously been identified in S. aureus strains associated with
mastitis infection [41]. The LF concentration in milk has been shown to increase in cows suffering
from subclinical mastitis [46], possibly as part of an immune response to infection. The results of this
study demonstrate that although S. aureus DPC 5971 binds to both colostrum and mature milk LF,
the glycoprofile present on mature milk LF is more favourable for bacterial binding, suggesting that
the S. aureus receptors which interact with LF are regulated by the glycosylation present on the protein.
Two E. coli O157:H7 strains were included in this study: E. coli P1432 and E. coli NCTC 12900;
the former was included as the negative control. O157 strains have previously been shown to be
unable to produce type 1 fimbriae (because of a deletion in the fim regulatory region) [42] described by
Teraguchi, Shin, Fukuwatari and Shimamura [23] as the mode of binding for E. coli cells to LF mannose
residues. Of interest, a recent study proposes a method for pathotyping E. coli based on type 1 fimbrial
interaction with a mannosylated surface using shear force [47]. Minimal binding was observed for
E. coli NCTC 12900 with mature milk LF. LF has been shown to bind to different E. coli strains with
varying levels of efficiency, for both the human and bovine variants of the protein [48,49].
Two C. sakazakii strains were exposed to immobilised LF in this study: C. sakazakii NCTC 8155,
a strain isolated from dried milk powder; and C. sakazakii DPC 6531, a brain tumour isolate. The
most significant binding was observed for C. sakazakii NCTC 8155. LF has been shown to display
anti-bacterial [50,51] and anti-infective [52] activity against C. sakazakii. This study confirms the direct
binding of LF to C. sakazakii, which may give further insight into its mode of antibacterial action, which
to date is believed to be dependent on the protein’s iron chelating ability. Galactoligosaccharides [53]
and LF-containing bovine whey powders [54] have previously been shown to inhibit the adherence
of Cronobacter strains to gastrointestinal cells and in some cases prevent invasion. For both strains, a
higher RU value was noted when the immobilised analyte was the mature milk glycovariant, again
highlighting the importance of the mature milk glycoprofile in bacterial binding. In relation to the strain
specificity observed for C. sakazakii, LF binds more intensely to the strain isolated from milk powder.
Milk powder is a common source of C. sakazakii contamination and the World Health Organisation
(WHO) has issued guidelines relating to the recommended minimum temperature for reconstitution
to reduce infection risk. Fortification of milk powders and infant milk formulas with LF as a secondary
hurdle to infection may further reduce the annual incidences of C. sakazakii infection, which are most
common in neonates, infants and immunocompromised adults.
Novel interactions for S. pneumoniae ATCC BAA-255 and P. aeruginosa ATCC 33354 with LF
were observed in this study, both interacting to a greater extent with the glycoprotein from mature
milk. Two proteins from S. pneumoniae which bind to human LF have previously been identified [55].
These proteins have been suggested to be elements of a novel virulence mechanism, harnessing LF’s
iron binding activity to overcome iron limitation at mucosal surfaces. Antibacterial activity against
P. aeruginosa has been observed upon exposure to a peptide derived from LF, lactoferricin B [56].
However, this is the first study, to the best of our knowledge, that demonstrates binding of bovine milk
derived LF to the whole bacterial cells. Both S. pneumoniae [57] and P. aeruginosa [58] have previously
been shown to have affinity for neutral oligosaccharides with terminal D-Gal residues, suggesting that
the complex type glycans in mature milk have a role to play in the binding of these strains. Complex
glycans have a higher level of sialylation in colostrum [7], inhibiting recognition of terminal Gal
residues by bacterial lectins. Therefore, the mature milk glycoprofile offers terminal D-Gal residues as
targets for bacterial binding.
S. typhimurium was the sole bacterial strain to show greater binding to colostrum LF. S. typhimurium
adhesion to intestinal cells has previously been shown to be linked to cellular glycosylation and can
be inhibited by lectins PNA, AIA, ECA, RCA I and WGA which compete for the glycan receptors
including Galβ(1–3)GalNAc on the epithelial cell surface [59]. Binding patterns of these lectins to LF
over lactation was previously profiled and all lectins displayed the highest interaction with colostrum
LF [7], suggesting the glycosylation profile of LF from early lactation is in some way homologous
Sensors 2017, 17, 1515 7 of 10
to the binding sites on Caco-2 cells for S. typhimurium. Although cows of all ages can be infected
with Salmonella bacteria, serious infections and deaths are most often seen in young calves [60].
The glycosylation pattern of LF in early lactation may contribute to the immune protection delivered
to the calf via its mother’s milk and may have evolved to offer protection against infections most likely
to occur in early life.
Colostrum LF has a higher N-acetylneuraminic acid (Neu5Ac) content compared to mature
milk LF [7] and this monosaccharide is closely linked to LF’s antibacterial activity, as previously
reviewed [6]. However, minimal bacterial binding to colostrum LF was observed in this study. This
suggests that bovine LF has two modes of action for its anti-microbial activity; transitioning from a
Neu5Ac dependent functionality in early lactation, to a more non-specific role in mature milk as a
decoy receptor, which can bind a number of pathogenic bacteria, preventing adhesion and infection.
This would suggest LF’s glycosylation changes over the lactation period to deliver the most optimum
protection relevant to the life-stage of the offspring.
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